Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis.
Messoud AshinaDimos D MitsikostasVerena Ramirez CamposSteve BarashXiaoping NingHans-Christoph DienerPublished in: Headache (2023)
The NNT, NNH, and LHH for quarterly and monthly fremanezumab compare favorably with those for traditional oral preventive medications, including topiramate, valproate, and propranolol.
Keyphrases